Results 111 to 120 of about 4,732,777 (361)

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.

Annals of Surgery, 2019
MINI: Total neoadjuvant therapy, or systemic induction chemotherapy followed by chemoradiation, is an optimal preoperative sequencing strategy for patients with borderline resectable or locally advanced pancreatic adenocarcinoma.
M. Truty, M. Kendrick, D. Nagorney, R. Smoot, S. Cleary, R. Graham, A. Goenka, C. Hallemeier, M. Haddock, W. Harmsen, A. Mahipal, R. McWilliams, T. Halfdanarson, A. Grothey   +13 more
semanticscholar   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Impact of Pathological Complete Response in Breast Cancer Following Neoadjuvant Therapy on Patient’s Outcome

, 2023
Rufina Soomro, Rabab Zehra
openalex   +2 more sources

DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway

Advanced Science, EarlyView.
Lenvatinib resistance poses a major challenge in advanced hepatocellular carcinoma (HCC). This study reveals that DNMT2 upregulation is a key driver, which stabilizes ACLY mRNA via m5C modification and activates the Notch signaling pathway. Crucially, combining ACLY inhibitors with lenvatinib overcomes resistance and suppresses tumors, offering a ...
Shiguang Yang, Jie Li, Shengwei Mao, Xuhui Zhao, Douwaner Liu, Jiafeng Chen, Jialu Fu, Yichao Bu, Xiaoling Wu, Shaoqing Liu, Qifeng Yu, Qiongzhu Dong, Zheng Tang, Yuan Fang, Yinghong Shi   +14 more
wiley   +1 more source

Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy [PDF]

, 2007
Julia Oh, Giang Nguyen, Gary J. Whitman, Kelly K. Hunt, Tse‐Kuan Yu, Wendy A. Woodward, Welela Tereffe, Eric A. Strom, George H. Perkins, Thomas A. Buchholz   +9 more
openalex   +1 more source

Prognosis and Quality of Life Analysis After Neoadjuvant Chemoradiotherapy and Primary Surgery for Low-lying Locally Advanced Rectal Cancer: Can Patients Benefit From Neoadjuvant Therapy? [PDF]

, 2021
Yaoyu Guo, Bang Hu, Hui Peng, Hongcheng Lin, Yongcheng Chen, Qi Zou, Dan Su, Di Zhang, Donglin Ren   +8 more
openalex   +1 more source

Pathomics Signature for Prognosis and CA19‐9 Interception in Pancreatic Ductal Adenocarcinoma: A Real‐Life, Multi‐Center Study

Advanced Science, EarlyView.
This study develops a deep learning‐based pathomics model to predict survival outcomes in pancreatic cancer patients. The CrossFormer architecture analyzes routine H&E‐stained tissue slides, identifying key prognostic features including stromal patterns, cellular characteristics, and immune infiltration.
Qiangda Chen, Zhihang Xu, Yiping Zou, Zhenlai Jiang, Yecheng Li, Taochen He, Hanlin Yin, Jiali Li, Yanfei An, Jiande Han, Yuqi Xie, Wei Gan, Yaolin Xu, Wenquan Wang, Junyi He, Haibo Wang, Wenchuan Wu, Zhenyu Ye, Wenhui Lou, Jihui Hao, Liang Liu, Jun Yu, Ning Pu   +22 more
wiley   +1 more source

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

Nature Medicine, 2022
W. Chatila, Jin K. Kim, H. Walch, Michael R. Marco, Ching-Tung Chen, Fan Wu, D. Omer, D. Khalil, K. Ganesh, X. Qu, A. Luthra, Seo-Hyun Choi, Yu-jui Ho, Ritika Kundra, Katharine I Groves, O. Chow, A. Cercek, M. Weiser, M. Widmar, I. Wei, E. Pappou, G. Nash, P. Paty, Q. Shi, E. Vakiani, S. Duygu Selcuklu, M. Donoghue, D. Solit, M. Berger, J. Shia, Raphael A. Pelossof, P. Romesser, R. Yaeger, J. Smith, N. Schultz, F. Sánchez-Vega, J. García-Aguilar   +36 more
semanticscholar   +1 more source

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

Science Translational Medicine, 2019
A robust personalized ctDNA test, TARDIS, achieves high accuracy for residual disease after completion of neoadjuvant therapy. Early detection, no time travel needed Analysis of tumor DNA shed into a patient’s circulation can provide a noninvasive means ...
B. R. McDonald, T. Contente-Cuomo, S. Sammut, Ahuva Odenheimer-Bergman, Brenda J Ernst, N. Perdigones, S. Chin, M. Farooq, Rosa Mejia, P. Cronin, K. Anderson, H. Kosiorek, D. Northfelt, A. McCullough, B. Patel, J. Weitzel, T. Slavin, C. Caldas, B. Pockaj, Muhammed Murtaza   +19 more
semanticscholar   +1 more source

Targeting IL27RA Enhances Immunotherapy in Triple‐Negative Breast Cancer by Modulating Tumor Cells and the Tumor Microenvironment

Advanced Science, EarlyView.
IL27RA upregulation drives immune evasion in TNBC by suppressing MHC‐I expression and reprogramming T/NK‐cell states, establishing an immune‐excluded tumor phenotype. Targeting this epithelial‐intrinsic IL27RA–PI3K/AKT axis offers a promising strategy to overcome immunotherapy resistance.
Jiachi Xu, Qian Long, Meirong Zhou, Qitong Chen, Jing Peng, Qingchun Liang, Danhua Zhang, Hui Zhou, Wenjun Yi   +8 more
wiley   +1 more source